CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine
2008; Elsevier BV; Volume: 26; Issue: 9 Linguagem: Inglês
10.1016/j.vaccine.2007.12.027
ISSN1873-2518
AutoresDubravka Grdic Eliasson, Karim El Bakkouri, Karin Schön, Anna Ramne, Els Festjens, Björn Löwenadler, Walter Fiers, Xavier Saelens, Nils Lycke,
Tópico(s)Immune Cell Function and Interaction
ResumoAt present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high M2e-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-M2e CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine.
Referência(s)